Medtronic (MDT) EBITDA (2014 - 2026)

Medtronic has disclosed EBITDA across 13 years of filings, most recently posting $1.8 billion for Q3 2026.

• In Q3 2026, EBITDA rose 22.08% year-over-year to $1.8 billion; the TTM figure through Jul 2026 stood at $6.8 billion (up 10.86% YoY), while the FY2026 annual figure was $6.5 billion, up 8.6% from the prior year.
• EBITDA came in at $1.8 billion for Q3 2026 at Medtronic, down from $1.9 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.9 billion in Q2 2026 to a low of $1.1 billion in Q2 2024.
• Average EBITDA over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2026.
• Year-over-year, EBITDA plunged 32.72% in 2024 and soared 36.37% in 2025.
• Over 5 years, EBITDA stood at $1.4 billion in 2022, then dropped by 4.56% to $1.3 billion in 2023, then climbed by 19.03% to $1.6 billion in 2024, then gained by 5.71% to $1.7 billion in 2025, then increased by 4.63% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $1.8 billion in Q3 2026, $1.9 billion in Q2 2026, and $1.5 billion in Q1 2026.